TCRX FY 2025 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$69M

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$136M

Net Income

-$130M

EPS (Diluted)

$-1.00

Cash Flow

Operating Cash Flow

-$135M

Free Cash Flow

-$140M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$229M

Total Liabilities

$106M

Stockholders' Equity

$123M

Cash & Equivalents

$152M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$3M	-100.0%
Gross Profit	$0	$3M	-100.0%
Operating Income	-$136M	-$135M	-0.7%
Net Income	-$130M	-$127M	-1.8%